Compare FLR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | PCVX |
|---|---|---|
| Founded | 1912 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 7.0B |
| IPO Year | 2006 | 2020 |
| Metric | FLR | PCVX |
|---|---|---|
| Price | $48.40 | $61.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $59.56 | ★ $116.40 |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $11.01 | N/A |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.33 | $42.40 |
| 52 Week High | $58.35 | $90.75 |
| Indicator | FLR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 47.18 |
| Support Level | $47.21 | $58.85 |
| Resistance Level | $49.85 | $62.44 |
| Average True Range (ATR) | 2.06 | 2.97 |
| MACD | 0.44 | -0.03 |
| Stochastic Oscillator | 61.18 | 26.56 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.